Sphera Funds Management LTD. raised its position in shares of vTv Therapeutics Inc. (NASDAQ:VTVT) by 50.0% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 300,000 shares of the biotechnology company’s stock after buying an additional 100,000 shares during the period. Sphera Funds Management LTD. owned approximately 3.10% of vTv Therapeutics worth $1,965,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Bank of New York Mellon Corp boosted its position in vTv Therapeutics by 6.1% in the first quarter. Bank of New York Mellon Corp now owns 22,780 shares of the biotechnology company’s stock worth $149,000 after buying an additional 1,305 shares in the last quarter. Essex Investment Management Co. LLC acquired a new position in vTv Therapeutics during the first quarter worth approximately $261,000. Renaissance Technologies LLC boosted its position in vTv Therapeutics by 24.3% in the fourth quarter. Renaissance Technologies LLC now owns 60,900 shares of the biotechnology company’s stock worth $294,000 after buying an additional 11,901 shares in the last quarter. Candriam Luxembourg S.C.A. acquired a new position in vTv Therapeutics during the first quarter worth approximately $917,000. Finally, Alyeska Investment Group L.P. boosted its position in vTv Therapeutics by 31.7% in the fourth quarter. Alyeska Investment Group L.P. now owns 213,200 shares of the biotechnology company’s stock worth $1,030,000 after buying an additional 51,301 shares in the last quarter. Hedge funds and other institutional investors own 11.63% of the company’s stock.
vTv Therapeutics Inc. (NASDAQ VTVT) traded down 2.48% during mid-day trading on Friday, hitting $4.71. The stock had a trading volume of 37,897 shares. The company’s market cap is $45.65 million. vTv Therapeutics Inc. has a one year low of $4.65 and a one year high of $7.50. The company has a 50 day moving average price of $5.05 and a 200-day moving average price of $5.46.
vTv Therapeutics (NASDAQ:VTVT) last released its earnings results on Wednesday, May 3rd. The biotechnology company reported ($0.44) EPS for the quarter, hitting analysts’ consensus estimates of ($0.44). The business had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.20 million. Equities analysts expect that vTv Therapeutics Inc. will post ($1.16) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “vTv Therapeutics Inc. (VTVT) Position Boosted by Sphera Funds Management LTD.” was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/06/16/vtv-therapeutics-inc-vtvt-position-raised-by-sphera-funds-management-ltd-updated-updated.html.
VTVT has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded vTv Therapeutics from a “hold” rating to a “buy” rating and set a $6.00 price objective on the stock in a report on Tuesday, May 9th. HC Wainwright set a $13.00 target price on vTv Therapeutics and gave the company a “buy” rating in a research report on Thursday, May 4th. Canaccord Genuity reissued a “buy” rating on shares of vTv Therapeutics in a research report on Tuesday, February 28th. Finally, Piper Jaffray Companies reissued an “overweight” rating and issued a $24.00 target price on shares of vTv Therapeutics in a research report on Thursday, March 30th. Five analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and an average target price of $14.30.
In other vTv Therapeutics news, Director Paul G. Savas bought 10,000 shares of the company’s stock in a transaction that occurred on Friday, March 31st. The shares were acquired at an average cost of $6.50 per share, for a total transaction of $65,000.00. Following the acquisition, the director now directly owns 66,435 shares of the company’s stock, valued at $431,827.50. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 0.80% of the stock is owned by insiders.
vTv Therapeutics Company Profile
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.
Receive News & Ratings for vTv Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.